Polyphor AG, corporate

Polyphor AG,

20.04.2017 - 13:37:42

EQS-News: Polyphor announces two oral and six poster presentations plus a press conference at the 27th ECCMID Congress, Vienna


EQS Group-News: Polyphor AG / Schlagwort(e): Konferenz

Polyphor announces two oral and six poster presentations plus a press

conference at the 27th ECCMID Congress, Vienna

20.04.2017 / 13:33

Polyphor announces two oral and six poster presentations plus a press

conference at the 27th ECCMID Congress, Vienna

Allschwil, Switzerland, 20 April, 2017. Polyphor announces today its

presence at ECCMID with two oral and six poster presentations on Murepavadin

(POL7080) and POL7001 as well as a press conference.

Dr Glenn Dale, Head of Early Development, Antimicrobials, Polyphor, and Dr

Anouk Muller, Medical Microbiology, Medisch Centrum Haaglanden, The Hague,

will give two oral presentations illustrating new data for Murepavadin

(POL7080), a novel Pseudomonas specific antibiotic being developed for

nosocomial pneumonia.

- Pharmacokinetics and pharmacodynamics of Murepavadin (POL7080) in

neutropenic lung infection models

- Population pharmacokinetics of Murepavadin (POL7080) and Monte Carlo

simulations to develop clinical dosing regimens, including the renally


The presentations will take place during the session OS201: PK/PD: "What you

need to learn from new and old-revived antibiotics" on Tuesday 25th April,

at 13.30-15.30 CET in Hall K.

In addition, five poster presentations on Murepavadin (POL7080) and one on

POL7001 will take place on Monday 24th April at 12.30- 13.30 CET, sessions

PO063 and PO068.

- In vitro drug transporter interaction studies with the outer membrane

protein targeting antibiotic Murepavadin (POL7080): Poster 2822

- Catabolism and Excretion of the Anti-Pseudomonal Peptidomimetic

Murepavadin (POL7080) in Humans: Poster 2748

- Population pharmacokinetics modeling of Murepavadin (POL7080) and

simulation of target attainment in a population with ventilator-associated

pneumonia due to infection with Pseudomonas Aeruginosa: Poster 2729

- Pharmacokinetic and efficacy analysis of Murepavadin (POL7080)

co-administered with standard-of-care (SoC) in a phase II study in patients

with ventilator-associated pneumonia (VAP) due to suspected or documented

Pseudomonas Aeruginosa infection: Poster 2720

- Pharmacokinetics of Murepavadin (POL7080) and amikacin in a drugdrug

interaction study in healthy subjects: Poster 2670

- POL7001 is highly efficacious in the murine neutropenic lung infection

model: Poster 2708

In addition, Polyphor will hold, a press conference, 'New hope in the battle

against antibiotic resistance - addressing a healthcare emergency', on

Monday 24th April, 18:15-19:15 CET at Room Krieau 2, Courtyard by Marriott

Vienna Prater/Messe, Trabrennstraße 4, 1020, Vienna.

Dr. Glenn Dale stated "We are pleased to have a significant presence at

ECCMID, a prestigious congress. We look forward to sharing new data with our

colleagues from across the globe and to demonstrate our commitment to

addressing pseudomonas infections and antibiotic resistance, one of the most

serious health threats of our time."

About Polyphor

Polyphor is a clinical stage, privately held Swiss specialty pharma company,

focused on the development of macrocycle drugs that address antibiotic

resistance and severe respiratory diseases. The company's lead drug

candidates include:

- Murepavadin (POL7080, in Phase II entering Phase III / Pivotal

registration program), a precision Outer Membrane Protein Targeting

Antibiotic (OMPTA) against Pseudomonas Aeruginosa.

- POL6014 (in Phase Ib), an inhaled inhibitor of neutrophil elastase for the

treatment of cystic fibrosis and other severe lung diseases.

- Balixafortide (POL6326, in Phase Ib), an antagonist of the chemokine

receptor CXCR4 for combination treatment in oncology.

Polyphor has discovered the OMPTA class and is further developing it,

including a broad-spectrum preclinical candidate, to address infections

caused by difficult-to-treat, resistant Gram-negative pathogens - one of the

most pressing emerging medical needs. The OMPTA represent the first new

class of antibiotics against Gram-negative bacteria reaching advanced

clinical stage in the last 40 years.

In addition, Polyphor has an important activity of discovery technology

partnerships to assist pharma companies in research programs addressing

difficult targets through its proprietary macrocycle technology platform.

Polyphor has several industry partnerships with and financing from the

Cystic Fibrosis Foundation Therapeutics, Gilead Sciences, Novartis, Taisho

and the Wellcome Trust.


Catherine Hof Jo Hewitt

Corporate Communications Director

Polyphor Ltd HAVAS Just::

Tel: +41 61 567 16 00 Tel: +44 208 877 8421

Email: [1]PR@polyphor.com Email: [1]jo@justhealthcomms.com

1. mailto:jo@justhealthcomms.com 1. mailto:jo@justhealthcomms.com

Zusatzmaterial zur Meldung:

Dokument: http://n.eqs.com/c/fncls.ssp?u=KTEEAJNCMN

Dokumenttitel: Poyphor_ECCM Congress

Ende der Medienmitteilung

565917 20.04.2017


@ dgap.de